Co looking to meet global domestic obligations with with 67% increase from 60m doses a month currently.
SII is set to increase its output of COVID-19 vaccines by 67% to 100 million doses per month from May, as it seeks to fulfill supply commitments domestically and globally.
The world’s largest vaccine manufacture is on track to achieve its fresh production target, up from 60 m doses a month currently, officials are aware of the development told ET.
SI didn’t reply to the email send by an ET. Chief executive Adar Poonawalla had told ET in an interview in Jan that the company would boost the manufacturing from May.
SII makes Covishield, which was developed by Astra Zeneca and the University of Oxford.
With India expanding vaccination coverage to include all those above the age of 45, there were concerns over whether the company would be able to meet its domestic and global requirements.
Pressure is also so mounting on the government to increase vaccination coverage due to the resurgence in infections.
India is averaging almost 1 million vaccinations a day.
However to cover at least 30% of core frontline workers, it needs to vaccinate at least 3 million people daily, which is a monthly requirement of 90 million doses every month.
Bharat Biotech’s Covaxin is the other vaccine that was approved for use in India.
Pressure on SII could ease if approvals come in for vaccines candidates that are at advanced stages of clinical trials – Russia’s Sputnik V and those from Cadila and Biological E.
Apart from India, SII is contractually bound to provide 270 million doses to COVAX global initiative.
India is the largest exporter of COVID-19 vaccines, according to data released by Swiss consulting firm Airfinity.